Levamisol não previne lesões de estomatite aftosa recorrente: um ensaio clínico randomizado, duplo-cego e controlado por placebo

Abstract

Levamisole, as used in this protocol, is a safe drug. When compared with the placebo, levamisole is not effective in the prophylactic treatment of recurrent aphthous stomatitis. The placebo effect is important in diseases where emotional factors affect recurrence or expression of symptoms.

Treatment of recurrent aphthous stomatitis. A literature review

“…Another immune modulator is levamisole, which restores normal phagocytic activity among macrophages and neutrophils, and modulates T cell mediated immunity. The drug shortens the duration of the aphthae outbreaks, as well as the number, size and frequency of the lesions (12,31). At a dose of 150 mg three times a week during 6 months, the drug is safe (31), though adverse effects have also been described, including nausea, hyperosmia, dysgeusia and agranulocytosis (12,31).…”

Babosa (Aloe Vera) e camomila (Matricaria chamomilla) no tratamento da estomatite aftosa recorrente

“…Os sintomas ocasionados levam o paciente a modificar seus hábitos diários, já que incluem dor e debilidade 13 . Também dificultam a fala, a mastigação e a deglutição, podendo levar à deficiência nutricional e comprometimento da qualidade de vida 14,15 .…”

Clinical application of a cocoa and unripe banana flour beverage for overweight women with abdominal obesity: Prospective, double-blinded and randomized clinical trial

“…However, it should be noted that the improvement of gastrointestinal symptoms observed in both groups may also be associated with a possible placebo effect. Studies have observed the interference of this effect on outcomes (Kalil et al, ; Weckx, Hirata, Abreu, Fillizolla, & Silva, ). Geers, Helfer, Weiland, and Kosbab () report that there is a correlation between the expectations created by individuals and the placebo effect.…”